Oncohematology in the Era of Immunotherapies: The Key Role of the Human Leukocyte Antigen (HLA) Complex
Cells · 19.11.2026 · 15 (22) · 2111
DOI: 10.3390/cells15222111 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 19.11.2026. Verfasst von Christophe Picard und 3 weiteren Autor:innen. Die Arbeit nennt 125 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Immunotherapy has transformed the therapeutic landscape of onco-hematology, evolving from historical allogeneic hematopoietic stem cell transplantation (HSCT) to modern chimeric antigen receptor (CAR) T/NK cell therapies, bispecific antibodies, and immune checkpoint inhibitors. Central to this immunological cross-talk is the Human Leukocyte Antigen (HLA) system, which governs self/non-self-discrimination, alloreactivity, and tumor immune evasion across both classical allografts and novel adoptive cellular platforms. Facing hematological malignancies, ranging from acute leukemias and multiple myeloma to chronic leukemias and lymphomas, clinicians must overcome tumor immune escape while managing treatment-related toxicities and Graft-versus-Host Disease (GvHD). Advances in high-throughput molecular biology techniques, notably Next-Generation Sequencing (NGS) and long-read sequencing, have become indispensable for high-resolution HLA matching, minimal residual disease (MRD) monitoring, and chimerism analysis. Furthermore, gene-editing strategies (e.g., CRISPR/Cas9) targeting TRAC, B2M, and CIITA, alongside HLA-E engineering and induced pluripotent stem cell (iPSC) technology, are driving the development of universal “off-the-shelf” effector platforms that bypass classic HLA barriers. In this review, we provide a conceptual synthesis of immunotherapeutic paradigms in onco-hematology, highlighting the pivotal role of HLA biology and molecular diagnostics in shaping next-generation personalized cellular therapies.
Zitieren
APA
Picard, C., Pedini, P., Costello, R., & Gabert, J. (2026). Oncohematology in the Era of Immunotherapies: The Key Role of the Human Leukocyte Antigen (HLA) Complex. Cells, 15(22), 2111. https://doi.org/10.3390/cells15222111
Vancouver
Picard C, Pedini P, Costello R, Gabert J. Oncohematology in the Era of Immunotherapies: The Key Role of the Human Leukocyte Antigen (HLA) Complex. Cells. 2026;15(22):2111. doi:10.3390/cells15222111
BibTeX
@article{Picard2026,
author = {Picard, Christophe and Pedini, Pascal and Costello, Régis and Gabert, Jean},
title = {Oncohematology in the Era of Immunotherapies: The Key Role of the Human Leukocyte Antigen (HLA) Complex},
journal = {Cells},
year = {2026},
volume = {15},
number = {22},
pages = {2111},
doi = {10.3390/cells15222111}
}
EUVIMED